Search Results
Your search for it matches 15746 pages
Showing 201 - 250Could A Telehealth Program Enhance Geriatric Cancer Care?
A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...
CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays
Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
Cutting Cancer Research Funding Is A Costly Gamble With Millions of Lives
“The [National Cancer Institute (NCI)] is a national treasure. If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years,” Richard J. Boxer, MD, wrote in an editorial Viewpoint published in JAMA Oncology ...
AACR Statement on Former President Joseph Biden’s Cancer Diagnosis
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers
In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals
The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Digital Histopathology and Automated Classification of Pediatric Sarcomas
With more than 50 different subtypes, pediatric soft-tissue sarcomas represent a broad category of disease. And given the rarity of these sarcomas, “it is difficult for pathologists to see a sufficient volume to gain expertise across all variants,” stated Adam Thiesen, BA, MD/PhD Candidate at UConn ...
Pathology Machine-Learning Models and Diagnosis of Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models, which were pretrained on vast data sets, outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, based on a session presented during the 2025 American Association for Cancer Research (AACR) Annual...
Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer
A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III or high-risk stage II colon cancer. These...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma
Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...
Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
ACS CAN Statement on Federal Cuts to Cancer Research
On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year. The following is a statement from...
Treatment for Intractable Cancer Pain Pioneered
A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...
Are Most Americans Aware of the Link Between Alcohol and Cancer Risk?
Although alcohol consumption is a known leading preventable cause of cancer, public awareness of the connection may remain concerningly low in the United States, according to a recent study published by Domgue et al in JAMA Oncology. Background Consuming alcohol has been linked to at least seven...
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
The first-in-class antibody-drug conjugate pivekimab sunirine was found to be safe and effective, with high response rates, in patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a phase I/II study presented at the 2025 ASCO Annual Meeting (Abstract 6502). These ...
Early Driver of Lineage Plasticity in Prostate Cancer Cells
Researchers have identified a gene that could play a key role in the transition to a more aggressive, treatment-resistant type of prostate cancer, according to a recent study published by Duan et al in the Journal of Clinical Investigation. The findings indicated that the gene may be indirectly...
Preoperative THP Leads to pCR in Two-Thirds of Patients With Early-Stage HER2-Positive ER-Negative Breast Cancer
Patients with stage II and III (early-stage) HER2-positive breast cancer usually undergo preoperative therapy with multiagent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced-chemotherapy treatment approach is currently being evaluated in the...
Novel Dual-Target CAR T-Cell Therapy May Slow Growth of Recurrent Glioblastoma
An investigational dual-target chimeric antigen receptor (CAR) T-cell therapy approach could slow tumor growth in patients with recurrent glioblastoma, according to new findings presented by Bagley et al at the 2025 ASCO Annual Meeting (Abstract 102) and simultaneously published in Nature ...
Married People May Have Better Colorectal Cancer Outcomes, Study Shows
Marital status significantly impacts survival rates for patients with colorectal cancer, according to a new Fox Chase Cancer Center study that was presented at the 2025 ASCO Annual Meeting (Abstract 3628). Married individuals were found to have better survival rates than single or separated and...
Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma
The combination of avelumab and cetuximab may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to recent findings presented by Zandberg et al at the 2025 ASCO Annual Meeting (Abstract 6002) and simultaneously...
Potential New Standard of Care Emerges in Multiple Myeloma
A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Presented ...
Trastuzumab Deruxtecan/Pertuzumab Leads to Improved PFS for HER2-Positive Breast Cancer
Results from the phase III DESTINY-Breast09 clinical trial found that the combination of fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab may delay cancer growth for longer than the current standard of care in people with HER2-positive locally advanced or metastatic breast cancer. The...
ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer
Switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to findings from the phase III SERENA-6 clinical trial. The research is...
Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer
A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...
Vepdegestrant Improves Progression-Free Survival in Select Patients With ESR1-Mutant Advanced Breast Cancer
Results from VERITAC-2 trial showed that the proteolysis-targeting chimera (PROTAC) vepdegestrant could extend progression-free survival for people with previously treated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with an ESR1 mutation. The research will be presented at...
Subset of Men With Rare Prostate Cancer May Benefit From Immunotherapy Added to Chemotherapy and Targeted Maintenance Therapy
Treatment options for aggressive-variant prostate cancer are limited, but a subset of patients have had promising long-term responses with a combination of carboplatin plus cabazitaxel chemotherapy, followed by PARP inhibitor maintenance. This novel combination treatment approach was the focus of a ...
Castor Oil
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Climate Change and Risk for Breast and Gynecologic Cancers
Climate change may be contributing to a small but notable increase in the incidence and mortality rates of breast, ovarian, endometrial, and cervical cancers in the Middle East and North Africa, according to a recent study published by Mataria and Chun in Frontiers in Public Health. Background...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Alcohol May Be Linked to Higher Risk of Pancreatic Cancer
Investigators may have uncovered a modest but potentially significant association between alcohol consumption and the risk of developing pancreatic cancer, according to a recent study published by Naudin et al in PLOS Medicine. Background Pancreatic cancer is the twelfth most common cancer type...
ESMO Releases Version 2.0 of the Magnitude of Clinical Benefit Scale
The European Society for Medical Oncology (ESMO) has announced the publication of the latest version of its scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale). The ESMO-MCBS was first introduced in 2015 and updated to version 1.1...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts
In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level1,2 and rescinding Biden Administration orders that emphasized the importance of these efforts to promote equal opportunity across government ...
Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma
The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case reports by Baldeep Wirk, MD, and Jin Lim, MD, PhD, both of Virginia Commonwealth University,...
What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?
Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...
In Case You Missed It: Additional Abstracts of Interest in Cancer Research
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management
Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless of the tumor type, researchers from Memorial Sloan Kettering (MSK) Cancer Center reported at the...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
